How We Help
Solutions
Pragmatic, science-driven solutions that translate regulatory complexity into clear development pathways and confident decisions across a broad range of modalities, for emerging biotechs, academic spinouts to mid-size companies, from pre-clinical to post-marketing we provide a range of solutions.
Modalities
BioV8 supports a broad range of therapeutic modalities across the development spectrum.
| Modality | Description |
|---|---|
| Small Molecules | Traditional chemical entities and synthetic drugs. |
| Biologics | Monoclonal antibodies, recombinant proteins, and peptides. |
| Cell & Gene Therapy | CAR-T, gene editing, and regenerative medicines. |
| Vaccines | Prophylactic and therapeutic vaccine platforms. |
| Oligonucleotides | ASOs, siRNA, mRNA, and gene-silencing therapeutics. |
| Radiopharmaceuticals | Diagnostic and therapeutic radioisotope agents. |
Company Type
Tailored engagement models aligned to your organization size and maturity.
| Company Type | Typical Focus |
|---|---|
| Emerging Biotech | First-in-human and proof-of-concept programs. |
| Mid-Size Pharma | Phase II/III expansion and global filings. |
| Virtual Pharma | Outsourced development and lean regulatory paths. |
| Academic Spinouts | Translational science and early-stage navigation. |
| Generics / Biosimilars | Equivalence, interchangeability, and 505(b)(2) pathways. |
Development Stage
Strategic regulatory support at every phase of the product lifecycle.
| Stage | Regulatory Focus |
|---|---|
| Preclinical / IND-Enabling | GLP tox, CMC readiness, and FDA pre-IND meetings. |
| Phase I | First-in-human safety, dose-escalation strategy, and SAD/MAD design. |
| Phase II | Proof-of-concept, patient selection, and adaptive trial designs, EOP2 Meeting. |
| Phase III | Pivotal efficacy, global protocol harmonization, and SPA alignment, Pre-NDA/BLA Meeting. |
| NDA / BLA / MAA | Module assembly, labeling negotiations, and agency interactions. |
| Post-Market / LCM | REMS, label expansion, Annual Reports, and pharmacovigilance strategy. |
Solution Type
Integrated service offerings designed to de-risk and accelerate your programs.
| Solution | What We Deliver |
|---|---|
| Regulatory Strategy | Pathway selection, agency meeting prep (Type A, B, C, D), and lifecycle planning. |
| CMC / Quality | Process validation, comparability, and post-approval changes. |
| Clinical Development | Protocol design, investigator support, and global trial strategy. |
| Medical Writing | IND/BLA/NDA modules, briefing books, and responses to FDA. |
| Quality by Design | Define critical quality attributes and manage risk to support development decisions and regulatory readiness. |